Japan· JP-4490410G2021
レブリキズマブ（遺伝子組換え）
A lebrikizumab product containing レブリキズマブ（遺伝子組換え）, registered in Japan by 日本イーライリリー, on the national reimbursement list. The same ATC class is registered in 15 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Lebrikizumab is registered in 15 of 19 countries.
Countries holding a registration under ATC D11AH10 (lebrikizumab), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 9 of them publish a price we can compare per daily dose
Lebrikizumab · ATC D11AH10
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of lebrikizumab costs, country by country.
Normalised to the WHO defined daily dose (8.9 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Lebrikizumab · price per daily dose (8.9 mg)
USD · FX 28 Sept 2026
- CH Switzerland$20.32
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- レブリキズマブ（遺伝子組換え）
- Manufacturer
- 日本イーライリリー
- Country
- Japan (JP)
- ATC code
- D11AH10
- ATC class
- Lebrikizumab
- Defined daily dose
- 8.9 mg, P
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Lebrikizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaEBGLYSSAlmirall, S.A., Barcelona
- SwitzerlandEbglyss
- United StatesEBGLYSSEli Lilly and Company
- NorwayEbglyssAlmirall, S.A.
- FranceEBGLYSS 250 mg, solution injectable en seringue préremplieALMIRALL (ESPAGNE)
- United KingdomEbglyss 250mg/2ml solution for injection pre-filled pensAlmirall Ltd
- BelgiumEbglyss 250 mgAlmirall
- IcelandEbglyssAlmirall S.A.*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Ebglyss
- Liechtenstein · Ebglyss
- Norway · Ebglyss
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/6c176cd7-8b48-4636-bbe9-b0b29febcbfe GET /v1/drugs/6c176cd7-8b48-4636-bbe9-b0b29febcbfe?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "２５０ｍｇ２ｍＬ１キット",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "4490410G2021",
"category": "注射薬",
"price_yen": 50782,
"generic_name": "レブリキズマブ（遺伝子組換え）",
"product_name_jp": null,
"therapeutic_class": "4490",
"transitional_expiry": null
}See everything about lebrikizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.